Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.87 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.87 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.87 |
| ▸ | LMNA | P02545 | 5/20 | 0.72 |
| ▸ | APEX1 | P27695 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6357013 | 0.93 | KMT2A (1.00) | KMT2ACYP1A2CYP2C19LMNAAPEX1 | |
| SCHEMBL24083684 | 0.92 | KMT2A (0.75) | KMT2ACYP1A2CYP2C19LMNAAPEX1 | |
| SCHEMBL15686617 | 0.91 | KMT2A (0.74) | KMT2ACYP1A2CYP2C19LMNAAPEX1 | |
| SCHEMBL12472363 | 0.90 | KMT2A (0.72) | KMT2ACYP1A2CYP2C19LMNAAPEX1 | |
| SCHEMBL12697363 | 0.89 | KMT2A (0.71) | KMT2ACYP1A2CYP2C19LMNAAPEX1 | |
| SCHEMBL28901311 | 0.89 | ALDH1A1 (0.73) | KMT2ACYP1A2CYP2C19LMNAAPEX1 | |
| SCHEMBL28053295 | 0.89 | KMT2A (0.70) | KMT2ACYP1A2CYP2C19LMNAAPEX1 | |
| SCHEMBL15686618 | 0.89 | KMT2A (0.70) | KMT2ACYP1A2CYP2C19LMNAAPEX1 | |
| SCHEMBL15686619 | 0.89 | KMT2A (0.70) | KMT2ACYP1A2CYP2C19LMNAAPEX1 | |
| SCHEMBL15686647 | 0.86 | HPGD (0.81) | KMT2ACYP1A2CYP2C19LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372915-A1 | MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-11-23 | — | — | US | disclosed |
| US-11731116-B2 | Manganese based complexes and uses thereof for homogeneous catalysis | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-08-22 | — | — | US | disclosed |
| WO-2017137984-A1 | MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-08-17 | — | — | WO | disclosed |
| US-8501992-B2 | Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2297103-B1 | HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| WO-2009152082-A1 | HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372915-A1 | MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS | ADH1C, OTC, MLEC | KMT2A 843/4885CYP1A2 2604/4885CYP2C19 2590/4885 |
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | KMT2A 2948/4885CYP1A2 3399/4885CYP2C19 4517/4885 |
| US-11731116-B2 | Manganese based complexes and uses thereof for homogeneous catalysis | ADH1C, OTC, ADH5 | KMT2A 990/4885CYP1A2 3168/4885CYP2C19 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.